Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions

Deficiency of glucocerebrosidase (GBA), a lysosomal beta-glucosidase, causes Gaucher disease. The enzyme hydrolyzes beta-glucosidic substrates and transglucosylates cholesterol to cholesterol-p-glucoside. Here we show that recombinant human GBA also cleaves beta-xylosides and transxylosylates cholesterol. The xylosyl-cholesterol formed acts as an acceptor for the subsequent formation of di-xylosyl-cholesterol. Common mutant forms of GBA from patients with Gaucher disease with reduced beta-glucosidase activity were similarly impaired in beta-xylosidase, transglucosidase, and transxylosidase activities, except for a slightly reduced xylosidase/glucosidase activity ratio of N370S GBA and a slightly reduced transglucosylation/glucosidase activity ratio of D409H GBA. XylChol was found to be reduced in spleen from patients with Gaucher disease. The origin of newly identified XylChol in mouse and human tissues was investigated. Cultured human cells exposed to exogenous beta-xylosides generated XylChol in a manner dependent on active lysosomal GBA but not the cytosol-facing beta-glucosidase GBA2. We later sought an endogenous beta-xyloside acting as donor in transxylosylation reactions, identifying xylosylated ceramide (XylCer) in cells and tissues that serve as donor in the formation of XylChol. UDP-glucosylceramide synthase (GCS) was unable to synthesize XylChol but could catalyze the formation of XylCer. Thus, food-derived beta-D-xyloside and XylCer are potential donors for the GBA-mediated formation of XylChol in cells. The enzyme GCS produces XylCer at a low rate. Our findings point to further catalytic versatility of GBA and prompt a systematic exploration of the distribution and role of xylosylated lipids.

Automated summary

Deficiency of glucocerebrosidase (GBA) causes Gaucher disease due to its complex catalytic functions, not only playing a key role in transglycosylation reactions, but also cleaving beta-xylosides. Patients with Gaucher disease have reduced GBA activity, leading to impaired related reactions.